Will Kyle Bass's Win Lead To More Hedge Fund Patent Challenges? – ValueWalk Premium
Kyle Bass

Will Kyle Bass's Win Lead To More Hedge Fund Patent Challenges?

As the sting of hedge fund manager Martin Shkreli’s Turing Pharmaceuticals raising the price of an important drug from $13.50 per tablet to $750, comes a victory for hedge fund manager Kyle Bass, who is challenging pharmaceutical patents and says his actions will lower drug prices.
U.S. Patent and Trademarket Office rules with Kyle Bass
In a victory for Bass, a tribunal at the U.S. Patent and Trademark Office was

SORRY!

This content is exclusively for paying members.

If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.


X
Saved Articles
X
TextTExtLInkTextTExtLInk
0